Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA-Reference-Cited by-同舟云学术

Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA

Published:2023-11-09 Issue:1 Volume:69 Page:228-234
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Valdés-Delgado Teresa,Aguado-Paredes Alicia,Merino-Bohórquez Vicente,Martín-Manzanares Jesús,Alonso María Mercedes,Maldonado Belén,Castro Luisa,Belvis María,Benítez Beatriz,Caunedo Ángel,Calleja Miguel Ángel,Argüelles-Arias Federico^ORCID

Funder

Grifols

Universidad de Sevilla

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

https://link.springer.com/content/pdf/10.1007/s10620-023-08139-1.pdf

Reference35 articles.

1. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–2476.

2. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 2005;128:862–869.

3. Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2009;2:101–109.

4. Brandse JF, Mathôt RA, van der Kleij D et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2016;14:251-258.e251-252.

5. Mould DR. The Pharmacokinetics of Biologics: A Primer. Digestive Diseases 2015;33:61–69.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A miniaturized platform based on reciprocating-flowing immunobinding for ultrafast, highly-sensitive and on-site immunoassay;Sensors and Actuators B: Chemical;2024-11

2. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2024-04-17